| Hazard Information | Back Directory | [Uses]
Ogremorphin (OGM) is a G protein coupled sensor GPR68 inhibitor with anti-inflammatory and anti-tumor activities. Ogremorphin can inhibit the migration of human melanoma cells and induce ferroptosis in glioblastoma cells[1][2][3]. | [in vivo]
Ogremorphin can alleviate vascular leakage, pulmonary inflammation, and pulmonary endothelial dysfunction caused by intratracheal injection of LPS or acidosis in mice[1].
Ogremorphin (10 μM) can cause abnormal melanocyte pigmentation and developmental disorders in zebrafish embryos[3]. | Animal Model: | Zebrafish[3]. | | Dosage: | 10 μM | | Administration: | Added to a 96 well microtiter plate (5 embryos/well) arranged with zebrafish fertilized eggs | | Result: | Induced phenotypes encompassing a wavy notochord, abnormal pigmentation, craniofacial defects, ventral curvature, and a shortened body axis. |
| [References]
[1] Karki P, et al. A Novel Group of Ogremorphin Inhibitors Targeting G Protein-coupled Sensor GPR68 Rescue Lipopolysaccharide or Acidosis-induced Lung Endothelial Dysfunction[M]//C108. MECHANISMS OF LUNG INFLAMMATION AND INFECTION. American Thoracic Society, 2024: A6846-A6846.
[2] Williams C H, et al. Coupling Metastasis to pH-Sensing GPR68 Using a Novel Small Molecule Inhibitor[J]. BioRxiv, 2019: 612549.
[3] Williams C H, et al. GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment. Exp Hematol Oncol. 2024 Jan 31;13(1):13. DOI:10.1186/s40164-023-00468-1 |
|
|